Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$21.16 -1.9%	$20.89	$17.24 ▼ $28.56	$13.57B	0.96	1.18 million shs	1.75 million shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$66.26 ▼ $131.98	$14.05B	0.69	1.57 million shs	N/A
SMMT Summit Therapeutics	$20.56 +2.0%	$23.76	$6.78 ▼ $36.91	$15.27B	-1.06	3.63 million shs	3.00 million shs
TPTX Turning Point Therapeutics	$76.01	$75.83	$23.77 ▼ $82.20	$3.81B	-0.18	1.14 million shs	4,322 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	0.00%	-7.27%	+1.68%	+9.69%	-18.71%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+0.13%	+72.20%
SMMT Summit Therapeutics	0.00%	+3.94%	-20.46%	-0.63%	+159.27%
TPTX Turning Point Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.7538 of 5 stars	3.3	5.0	0.0	0.0	2.0	0.0	3.1
ITCI Intra-Cellular Therapies	0.6987 of 5 stars	1.1	0.0	0.0	4.5	0.0	1.7	0.6
SMMT Summit Therapeutics	3.1301 of 5 stars	4.4	3.0	0.0	0.0	2.7	1.7	0.0
TPTX Turning Point Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	85.10% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
SMMT Summit Therapeutics	2.77	Moderate Buy	$35.09	70.68% Upside
TPTX Turning Point Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TPTX, SMMT, GMAB, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00
4/23/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.35	$1.52 per share	13.95	$8.04 per share	2.63
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
SMMT Summit Therapeutics	$700K	21,813.28	N/A	N/A	$0.53 per share	38.79
TPTX Turning Point Therapeutics	$30.83M	123.46	N/A	N/A	$15.84 per share	4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	12.02	11.89	6.98	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TPTX Turning Point Therapeutics	-$236.55M	-$6.90	N/A	N/A	N/A	N/A	-37.45%	-35.62%	N/A

Latest TPTX, SMMT, GMAB, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TPTX Turning Point Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.34	5.32
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	10.63	10.63
TPTX Turning Point Therapeutics	N/A	16.83	16.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
TPTX Turning Point Therapeutics	90.33%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	84.90%
TPTX Turning Point Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.22 million	631.35 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TPTX Turning Point Therapeutics	250	50.07 million	45.77 million	Not Optionable

TPTX, SMMT, GMAB, and ITCI Headlines

Recent News About These Companies

BMS sets up Roche, Pfizer rivalry with Turning Point takeover

May 20, 2025 | pharmaphorum.com

Digging Into Turning Point USA’s Role in the Trump 2024 Ground Game

October 8, 2024 | talkingpointsmemo.com

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance

September 29, 2024 | markets.businessinsider.com

Digital therapeutics at a turning point: What we heard at DTx East

September 14, 2024 | pharmaphorum.com

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

August 9, 2024 | seekingalpha.com

TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript

August 6, 2024 | seekingalpha.com

Viking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call Transcript

July 25, 2024 | seekingalpha.com

Glass System in Turning Point Residence

April 2, 2024 | archdaily.com

Bid to remove prosecutors sets up turning point in Trump’s Georgia case

February 19, 2024 | politico.com

Turning Point Brands Inc.

February 17, 2024 | wsj.com

Alzheimer’s: A Turning Point?

February 12, 2024 | bbc.co.uk

Turning Point Brands Inc (TPB)

February 10, 2024 | investing.com

Cormorant Asset Management, LP's Net Worth

February 10, 2024 | benzinga.com

Solving quadratic equations - Edexcel

January 15, 2024 | bbc.co.uk

COP15: A Turning Point for Investor Approaches to Biodiversity

December 19, 2023 | morningstar.com

Turning Point USA: Are conservatives fighting back on campus?

December 16, 2023 | bbc.com

BMS bet looking good as Augtyro approved in ROS1-positive NSCLC

November 16, 2023 | thepharmaletter.com

PhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in blood

October 29, 2023 | ulster.ac.uk

A Turning Point for Japan-US Climate Cooperation?

October 28, 2023 | thediplomat.com

What to know about the Turning Point USA incident on Arizona State University's campus

October 28, 2023 | azcentral.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPTX, SMMT, GMAB, and ITCI Company Descriptions

Genmab A/S NASDAQ:GMAB

$21.16 -0.40 (-1.86%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$21.60 +0.44 (+2.06%)

As of 06/20/2025 06:49 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$20.56 +0.40 (+1.98%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$20.30 -0.26 (-1.27%)

As of 06/20/2025 07:52 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time